home / stock / igms / igms message board
Subject | By | Source | When |
---|---|---|---|
bears are running | crudeoil24 | investorshub | 06/21/2023 6:16:13 AM |
short squeeze signal | TheFinalCD | investorshub | 05/29/2023 1:56:07 PM |
AviseAnalytics: 5 THINGS YOU MUST KNOW ABOUT IGM BIOSCIENCES! $IGMS IGM Biosciences, Inc. (NASDAQ: | AviseAnalytics | investorshangout | 04/01/2022 1:02:41 PM |
Truist Reiterates Buy Rating, $80 Price Target. | crudeoil24 | investorshub | 03/29/2022 5:20:52 PM |
Let's see if $IGMS gets FDA phase | crudeoil24 | investorshub | 03/29/2022 4:57:42 PM |
14M float! | crudeoil24 | investorshub | 03/29/2022 4:54:58 PM |
Tons of cash going forward > IGM Biosciences, | crudeoil24 | investorshub | 03/29/2022 4:40:20 PM |
https://ih.advfn.com/stock-market/NASDAQ/igm-biosciences-IGMS/stock-news/87682546/igm-announces-prop | TheFinalCD | investorshub | 03/29/2022 4:05:17 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-10-01 07:59:56 ET Asthika Goonewardene from Truist Financial issued a price target of $12.00 for IGMS on 2024-10-01 06:52:00. The adjusted price target was set to $12.00. At the time of the announcement, IGMS was trading at $16.54. The overall price target consensus...
– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus – – Mary Beth Harler, M.D., appointed as Chief Executive Officer and to Board o...
MOUNTAIN VIEW, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, and Mary Beth Harler, M.D., Head, Research & ...